Clinical Report: Assessing Quality of Life in Neovascular AMD Pre- and Post-Treatment

Overview

This study evaluates the impact of intravitreal injections on vision-related quality of life in patients with neovascular age-related macular degeneration (nAMD). Results indicate a statistically significant improvement in quality of life following treatment, correlated with visual function parameters.

Background

Neovascular age-related macular degeneration is a leading cause of vision loss in older adults, significantly affecting quality of life. The condition is characterized by progressive visual impairment, which can hinder daily activities and overall well-being. Understanding the effects of treatment on quality of life is crucial for optimizing patient care and adherence to therapy.

Data Highlights

Key Findings

• 121 patients (60 women, 61 men) aged 51-90 were included in the study.
• Significant improvement in vision-related quality of life post-treatment was observed.
• Better visual acuity and contrast sensitivity were associated with higher quality of life scores.
• Fewer visual disturbances correlated with improved quality of life.
• The study underscores the psychosocial benefits of intravitreal therapy in nAMD.

Clinical Implications

Clinicians should consider the psychosocial aspects of treatment when managing patients with nAMD. The observed improvements in quality of life following intravitreal therapy may enhance patient adherence to treatment regimens.

Conclusion

The study demonstrates that intravitreal anti-VEGF therapy can lead to modest improvements in quality of life for patients with neovascular age-related macular degeneration, highlighting the importance of addressing both clinical and psychosocial outcomes in treatment plans.

Related Resources & Content

1. Retinal Physician, 2015 -- CLINICAL TRIAL UPDATE
2. Retinal Physician, 2009 -- Clinical Trials Update
3. Retinal Physician, 2015 -- CLINICAL TRIAL UPDATE
4. Retinal Physician, 2019 -- CLINICAL TRIAL UPDATE
5. Age-Related Macular Degeneration Preferred Practice Pattern® - PubMed
6. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR)
7. Quality of life in patients with neovascular age-related macular degeneration before and after intravitreal therapy
8. Age-Related Macular Degeneration Preferred Practice Pattern® - PubMed
9. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial - PubMed
10. Frontiers | Quality of life in patients with neovascular age-related macular degeneration before and after intravitreal therapy: a longitudinal observational study